Johnson & Johnson (NYSE:JNJ) Shares Sold by NORTHSTAR ASSET MANAGEMENT Co LLC

NORTHSTAR ASSET MANAGEMENT Co LLC cut its position in Johnson & Johnson (NYSE:JNJ) by 0.7% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 21,376 shares of the company’s stock after selling 150 shares during the quarter. NORTHSTAR ASSET MANAGEMENT Co LLC’s holdings in Johnson & Johnson were worth $3,091,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of JNJ. Opal Wealth Advisors LLC raised its stake in Johnson & Johnson by 27.1% during the 4th quarter. Opal Wealth Advisors LLC now owns 2,383 shares of the company’s stock valued at $345,000 after acquiring an additional 508 shares in the last quarter. Wingate Wealth Advisors Inc. acquired a new position in shares of Johnson & Johnson during the fourth quarter valued at $233,000. Savant Capital LLC raised its stake in shares of Johnson & Johnson by 0.3% during the fourth quarter. Savant Capital LLC now owns 248,256 shares of the company’s stock valued at $35,903,000 after purchasing an additional 729 shares in the last quarter. Angeles Wealth Management LLC grew its position in Johnson & Johnson by 2.1% in the 4th quarter. Angeles Wealth Management LLC now owns 16,166 shares of the company’s stock valued at $2,338,000 after buying an additional 329 shares in the last quarter. Finally, Tevis Investment Management increased its stake in Johnson & Johnson by 2.1% during the 4th quarter. Tevis Investment Management now owns 17,692 shares of the company’s stock valued at $2,559,000 after buying an additional 358 shares during the period. 69.55% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

JNJ has been the subject of a number of research analyst reports. Leerink Partners reduced their price target on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a research note on Thursday, January 23rd. Raymond James cut their target price on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a research report on Thursday, January 23rd. Wolfe Research initiated coverage on Johnson & Johnson in a research note on Friday, November 15th. They issued an “outperform” rating and a $190.00 price objective on the stock. Morgan Stanley decreased their target price on Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a research note on Thursday, January 23rd. Finally, Stifel Nicolaus dropped their price target on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a research report on Thursday, January 23rd. Nine investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $170.67.

Insider Activity at Johnson & Johnson

In related news, Director Mark A. Weinberger bought 1,000 shares of the firm’s stock in a transaction on Thursday, December 12th. The stock was bought at an average price of $147.22 per share, with a total value of $147,220.00. Following the purchase, the director now directly owns 1,000 shares of the company’s stock, valued at approximately $147,220. This represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Trading Up 1.3 %

NYSE JNJ opened at $157.24 on Friday. The firm’s 50 day moving average price is $147.58 and its two-hundred day moving average price is $156.00. The stock has a market cap of $378.58 billion, a price-to-earnings ratio of 23.65, a PEG ratio of 2.46 and a beta of 0.52. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $168.85. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The firm had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. During the same period in the previous year, the firm earned $2.29 earnings per share. Johnson & Johnson’s quarterly revenue was up 5.3% on a year-over-year basis. Equities analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be issued a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 3.15%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is currently 74.59%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.